Back to News
Market Impact: 0.2
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition
Source: Nasdaq
Healthcare & BiotechCorporate Guidance & OutlookCompany Fundamentals
Johnson & Johnson said it remains on track to grow despite biosimilar competition for its STELARA treatment. Management expects its medicines, medical-devices and pipeline portfolio to support growth, positioning JNJ as a defensive stock as CPI data and Federal Reserve policy test the broader market rally.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
JNJ0.35
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Microsoft's Big Bets on AI Start to Pay Off
- Google's Gemini 4 Carbon looks like a diamond in the rough